Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Mar 2022. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4970529012 | Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 4970530019 | Alogliptin (as alogliptin benzoate) 12.5 mg and pioglitazone (as pioglitazone hydrochloride) 45 mg oral tablet | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only alogliptin and pioglitazone in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Pioglitazone hydrochloride | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Pioglitazone | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Alogliptin benzoate | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Alogliptin | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR